Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pulmatrix, Inc. (PULM : NSDQ)

• Company Description    Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $6.20 Daily Weekly Monthly 20 Day Moving Average: 7,844 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 1.38 52 Week High: $10.40 52 Week Low: $1.72 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.81% 8.80% 12 Week -19.79% -13.35% Year To Date -11.18% -7.70%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 945 CONCORD STREET SUITE 1217 - FRAMINGHAM,MA 01701 USA ph: 888-355-4440 fax: 707-525-9906 tim@lifesciadvisors.com http://www.pulmatrix.com

• General Corporate Information    Officers Peter Ludlum - Interim Chief Executive Officer and Interim Chief Michael J. Higgins - Chairman Richard Batycky - Director Todd Bazemore - Director Christopher Cabell - Director Peer Information Pulmatrix, Inc. (CORR.) Pulmatrix, Inc. (RSPI) Pulmatrix, Inc. (CGXP) Pulmatrix, Inc. (BGEN) Pulmatrix, Inc. (GTBP) Pulmatrix, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74584P301 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/24 Next Expected EPS Date: 05/09/25 Share - Related Items Shares Outstanding: Most Recent Split Date: 3.00 (0.05:1) Beta: 1.38 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/09/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.53 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 5.26% vs. Previous Quarter: 23.94% Sales Growth vs. Year Ago Period: -99.86% vs. Previous Quarter: -99.18% ROE 03/31/25 - - 12/31/24 - -53.19 09/30/24 - -45.97 ROA 03/31/25 - - 12/31/24 - -41.06 09/30/24 - -30.72 Current Ratio 03/31/25 - - 12/31/24 - 10.68 09/30/24 - 19.40 Quick Ratio 03/31/25 - - 12/31/24 - 10.68 09/30/24 - 19.40 Operating Margin 03/31/25 - - 12/31/24 - -88.92 09/30/24 - -70.35 Net Margin 03/31/25 - - 12/31/24 - -122.46 09/30/24 - -96.51 Pre-Tax Margin 03/31/25 - - 12/31/24 - -88.92 09/30/24 - -96.51 Book Value 03/31/25 - - 12/31/24 - 2.45 09/30/24 - 2.99 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - - 12/31/24 - 0.00 09/30/24 - 0.00 Debt-to-Capital 03/31/25 - - 12/31/24 - 0.00 09/30/24 - 0.00

Powered by Zacks Investment Research ©